SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Heart Disease: A Literature Review
Sodium-glucose transport protein 2 inhibitors, commonly referred to as SGLT2i, are a group of prescription pharmaceuticals that are approved by the United States Food and Drug Administration for use with diet and exercise to lower blood glucose in adults with type 2 diabetes. Diabetes is a well-reco...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Houston Methodist DeBakey Heart & Vascular Center
2022-09-01
|
| Series: | Methodist DeBakey Cardiovascular Journal |
| Subjects: | |
| Online Access: | https://account.journal.houstonmethodist.org/index.php/up-j-mdbcj/article/view/1120 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849329990294831104 |
|---|---|
| author | Abhishek Kansara Faiza Mubeen Jawairia Shakil |
| author_facet | Abhishek Kansara Faiza Mubeen Jawairia Shakil |
| author_sort | Abhishek Kansara |
| collection | DOAJ |
| description | Sodium-glucose transport protein 2 inhibitors, commonly referred to as SGLT2i, are a group of prescription pharmaceuticals that are approved by the United States Food and Drug Administration for use with diet and exercise to lower blood glucose in adults with type 2 diabetes. Diabetes is a well-recognized major contributor to cardiovascular and renal disease burden. In addition to blood glucose control, SGLT2i have been shown to provide significant cardiovascular and renoprotective benefits in patients with and without diabetes. In this review, we describe current evidence related to the renal and cardiovascular benefits of using SGLT2i. |
| format | Article |
| id | doaj-art-85830d685c984687b51fc6869eb12a7e |
| institution | Kabale University |
| issn | 1947-6108 |
| language | English |
| publishDate | 2022-09-01 |
| publisher | Houston Methodist DeBakey Heart & Vascular Center |
| record_format | Article |
| series | Methodist DeBakey Cardiovascular Journal |
| spelling | doaj-art-85830d685c984687b51fc6869eb12a7e2025-08-20T03:47:06ZengHouston Methodist DeBakey Heart & Vascular CenterMethodist DeBakey Cardiovascular Journal1947-61082022-09-01184627210.14797/mdcvj.1120484SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Heart Disease: A Literature ReviewAbhishek Kansara0https://orcid.org/0000-0002-3686-1035Faiza Mubeen1https://orcid.org/0000-0001-9887-0669Jawairia Shakil2Houston Methodist Hospital, Houston, Texas; Weill Cornell College of Medicine, Ithaca, New York; Texas A&M College of Medicine, Houston, TexasHouston Methodist Hospital, Houston, TexasHouston Methodist Hospital, Houston, Texas; Weill Cornell College of Medicine, Ithaca, New York; Texas A&M College of Medicine, Houston, TexasSodium-glucose transport protein 2 inhibitors, commonly referred to as SGLT2i, are a group of prescription pharmaceuticals that are approved by the United States Food and Drug Administration for use with diet and exercise to lower blood glucose in adults with type 2 diabetes. Diabetes is a well-recognized major contributor to cardiovascular and renal disease burden. In addition to blood glucose control, SGLT2i have been shown to provide significant cardiovascular and renoprotective benefits in patients with and without diabetes. In this review, we describe current evidence related to the renal and cardiovascular benefits of using SGLT2i.https://account.journal.houstonmethodist.org/index.php/up-j-mdbcj/article/view/1120sglt2 inhibitorscardiovascular outcomesrenal outcomesheart failurediabetic ketoacidosisdka |
| spellingShingle | Abhishek Kansara Faiza Mubeen Jawairia Shakil SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Heart Disease: A Literature Review Methodist DeBakey Cardiovascular Journal sglt2 inhibitors cardiovascular outcomes renal outcomes heart failure diabetic ketoacidosis dka |
| title | SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Heart Disease: A Literature Review |
| title_full | SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Heart Disease: A Literature Review |
| title_fullStr | SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Heart Disease: A Literature Review |
| title_full_unstemmed | SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Heart Disease: A Literature Review |
| title_short | SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Heart Disease: A Literature Review |
| title_sort | sglt2 inhibitors in patients with chronic kidney disease and heart disease a literature review |
| topic | sglt2 inhibitors cardiovascular outcomes renal outcomes heart failure diabetic ketoacidosis dka |
| url | https://account.journal.houstonmethodist.org/index.php/up-j-mdbcj/article/view/1120 |
| work_keys_str_mv | AT abhishekkansara sglt2inhibitorsinpatientswithchronickidneydiseaseandheartdiseasealiteraturereview AT faizamubeen sglt2inhibitorsinpatientswithchronickidneydiseaseandheartdiseasealiteraturereview AT jawairiashakil sglt2inhibitorsinpatientswithchronickidneydiseaseandheartdiseasealiteraturereview |